Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

450 brain tumor patients reveal key survival clues

NCT ID NCT07342699

Knowledge-focused Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked back at 450 people who had surgery for a rare type of brain tumor (cerebellar glioma). Researchers wanted to see if where the tumor was located and its genetic makeup could predict how much of the tumor could be safely removed and how long patients lived. The goal is to help doctors better plan treatment and predict outcomes for future patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

450 people

The number who actually took part.

Started

Jan 2014

Finished

Jun 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study Population Description The study group is 450 consecutive patients treated at a single high-volume neuro-oncology center (West China Hospital and its Longquan branch) who underwent primary microsurgical resection for a newly diagnosed glioma that arose wholly within the cerebellum. * \*\*Age span\*\*: 3-78 years (median 38 years); 52.7 % ≤ 40 y, 47.3 % \> 40 y * \*\*Sex\*\*: 244 males (54.3 %), 206 females (45.7 %) * \*\*Tumor origin by cerebellar sub-site\*\* * Cerebellar hemisphere 223 (49.6 %) * Vermis 141 (31.3 %) * Fourth ventricle 67 (14.9 %) * Pontocerebellar-angle region 19 (4.2 %) * \*\*WHO grade at resection\*\*: Low-grade (I-II) 291 (64.7 %); High-grade (III-IV) 159 (35.3 %) * \*\*Pre-operative functional status\*\*: Median KPS 80 (IQR 70-90) * \*\*Molecular profile (full cohort tested)\*\* * IDH-mutant 152 (33.7 %), IDH-wild-type 298 (66.3 %) * 1p/19q codeleted 97 (21.5 %) * MGMT promoter methylated 161 (35.7 %) * TERT promoter mutant 83 (18.4 %)

Ages

3 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Pathologically proven cerebellar glioma (hemisphere, vermis, fourth ventricle, or pontocerebellar-angle region) per 2021 WHO CNS classification * First microsurgical resection performed at our center between January 2014 and January 2024 * Age ≥ 3 years at surgery * Pre-operative Karnofsky Performance Status (KPS) recorded * Availability of post-operative contrast MRI for resection-extent calculation * Minimum required molecular data: IDH1/2 status (immunohistochemistry ± sequencing) * Continuous follow-up ≥ 6 months after surgery (out-patient visits or telephone confirmation) Exclusion Criteria * Brain-stem glioma with secondary cerebellar invasion * Recurrent or metastatic glioma * Previous cranial radiation or glioma surgery at another institution * Palliative resection (\< 20 % of tumor volume removed) * Missing post-operative MRI or insufficient tissue for mandatory IDH testing * Follow-up \< 6 months or lost to follow-up before 6-month landmark

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cerebellar glioma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebellar astrocytoma glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gliomas

Contacts and locations

Locations

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.